328 related articles for article (PubMed ID: 21562147)
1. Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose.
Zhang X; Li L; Ding X; Kaminsky LS
Drug Metab Dispos; 2011 Aug; 39(8):1433-9. PubMed ID: 21562147
[TBL] [Abstract][Full Text] [Related]
2. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.
Özer M; Demirci Y; Hizel C; Sarikaya S; Karalti İ; Kaspar Ç; Alpan S; Genç E
Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):209-14. PubMed ID: 23061746
[TBL] [Abstract][Full Text] [Related]
3. Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.
Liang R; Li L; Li C; Gao Y; Liu W; Hu D; Sun Y
J Thromb Thrombolysis; 2012 Jul; 34(1):120-5. PubMed ID: 22528326
[TBL] [Abstract][Full Text] [Related]
4. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.
Cen HJ; Zeng WT; Leng XY; Huang M; Chen X; Li JL; Huang ZY; Bi HC; Wang XD; He YL; He F; Zhou RN; Zheng QS; Zhao LZ
Br J Clin Pharmacol; 2010 Aug; 70(2):234-40. PubMed ID: 20653676
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 oxidoreductase genetic polymorphisms A503V and rs2868177 do not significantly affect warfarin stable dosage in Han-Chinese patients with mechanical heart valve replacement.
Tan SL; Li Z; Zhang W; Song GB; Liu LM; Peng J; Liu ZQ; Fan L; Meng XG; Wang LS; Chen Y; Zhou XM; Zhou HH
Eur J Clin Pharmacol; 2013 Oct; 69(10):1769-75. PubMed ID: 23949431
[TBL] [Abstract][Full Text] [Related]
6. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
[TBL] [Abstract][Full Text] [Related]
7. Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin.
Ma C; Zhang Y; Xu Q; Yang J; Zhang Y; Gao L; Xu B; Wang H; Li Y; Lu C; Yin T
Int J Hematol; 2012 Dec; 96(6):719-28. PubMed ID: 23104259
[TBL] [Abstract][Full Text] [Related]
8. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.
Takeuchi F; McGinnis R; Bourgeois S; Barnes C; Eriksson N; Soranzo N; Whittaker P; Ranganath V; Kumanduri V; McLaren W; Holm L; Lindh J; Rane A; Wadelius M; Deloukas P
PLoS Genet; 2009 Mar; 5(3):e1000433. PubMed ID: 19300499
[TBL] [Abstract][Full Text] [Related]
9. Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients.
Zhong SL; Yu XY; Liu Y; Xu D; Mai LP; Tan HH; Lin QX; Yang M; Lin SG
Pharmacogenet Genomics; 2012 Mar; 22(3):176-82. PubMed ID: 22198820
[TBL] [Abstract][Full Text] [Related]
10. Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.
Krishna Kumar D; Shewade DG; Loriot MA; Beaune P; Balachander J; Sai Chandran BV; Adithan C
Eur J Clin Pharmacol; 2014 Jan; 70(1):47-56. PubMed ID: 24019055
[TBL] [Abstract][Full Text] [Related]
11. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.
Rusdiana T; Araki T; Nakamura T; Subarnas A; Yamamoto K
Eur J Clin Pharmacol; 2013 Mar; 69(3):395-405. PubMed ID: 22855348
[TBL] [Abstract][Full Text] [Related]
12. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.
Borgiani P; Ciccacci C; Forte V; Romano S; Federici G; Novelli G
Pharmacogenomics; 2007 Nov; 8(11):1545-50. PubMed ID: 18034619
[TBL] [Abstract][Full Text] [Related]
13. Resequencing of VKORC1, CYP2C9 and CYP4F2 genes in Italian patients requiring extreme low and high warfarin doses.
Di Fusco D; Ciccacci C; Rufini S; Forte V; Novelli G; Borgiani P
Thromb Res; 2013 Jul; 132(1):123-6. PubMed ID: 23726967
[TBL] [Abstract][Full Text] [Related]
14. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes.
Teichert M; Eijgelsheim M; Uitterlinden AG; Buhre PN; Hofman A; De Smet PA; Visser LE; Stricker BH
Pharmacogenet Genomics; 2011 Jan; 21(1):26-34. PubMed ID: 21063236
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response.
Shalia KK; Doshi SM; Parikh S; Pawar PP; Divekar SS; Varma SP; Mehta R; Doctor T; Shah VK; Saranath D
J Assoc Physicians India; 2012 Dec; 60():34-8. PubMed ID: 23781667
[TBL] [Abstract][Full Text] [Related]
17. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
[TBL] [Abstract][Full Text] [Related]
18. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients.
Shahin MH; Khalifa SI; Gong Y; Hammad LN; Sallam MT; El Shafey M; Ali SS; Mohamed ME; Langaee T; Johnson JA
Pharmacogenet Genomics; 2011 Mar; 21(3):130-5. PubMed ID: 21228733
[TBL] [Abstract][Full Text] [Related]
19. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
[TBL] [Abstract][Full Text] [Related]
20. CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects.
Nakamura K; Obayashi K; Araki T; Aomori T; Fujita Y; Okada Y; Kurabayashi M; Hasegawa A; Ohmori S; Nakamura T; Yamamoto K
J Clin Pharm Ther; 2012 Aug; 37(4):481-5. PubMed ID: 22172097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]